Sacramento, CA Clinical Trials Report — June 2026

For Sacramento residents considering participation in clinical research, June 2026 presents a crucial window of opportunity, particularly for trials nearing their enrollment deadlines. Across Sacramento, CA, a total of 42 clinical trials are slated to conclude within the next 90 days, making prompt action essential for interested individuals.

Among these rapidly closing studies, 10 are actively seeking healthy volunteers, offering a chance to contribute to medical advancements before their enrollment windows close. This provides an immediate opportunity for individuals without specific health conditions to participate in research.

Impending Deadlines for Diverse Conditions

Patients managing specific health conditions also have limited time remaining to join research. Trials focused on various conditions are among those with impending deadlines for enrollment:

• Scarring (2 trials)
• Alopecia Areata (1 trial)
• Benign Prostatic Hyperplasia (BPH) (1 trial)
• Asplenia (1 trial)
• Asthma (1 trial)
• Atopic Dermatitis (1 trial)
• Alzheimer Disease (1 trial)
• Breast Cancer (1 trial)
• Breast Cancer Screening (1 trial)
• Breast Carcinoma In Situ (1 trial)

New Research Opportunities Emerge This Month

This month, Sacramento saw the opening of 6 new clinical trials. While this is a slight decrease from the 7 trials that launched in May 2026, it adds to the city's robust research landscape, which currently includes 553 actively recruiting clinical trials across 216 research facilities.

June brings several notable new trials to Sacramento, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Eli Lilly and Company is sponsoring a notable Phase 3 study, NCT07668336, "A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes." This study aims for 170 participants and looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check the safety of these medicines and how the body processes them.
• AstraZeneca is initiating a Phase IIb study, NCT07652658, "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF." This study aims for 359 participants to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF), including those on antifibrotic therapy or those not on antifibrotic treatment.
• Vanderbilt University Medical Center is sponsoring NCT07674758, "Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials." This research aims for 1,000 participants to better understand the evolution of heart dysfunction in patients with Duchenne and Becker Muscular Dystrophy (DMD/BMD) and Duchenne and Becker muscular dystrophy carriers (MDC), as dystrophin associated heart dysfunction is a leading cause of death.

New trials this month are exploring a range of conditions, with new opportunities for patients with:

• Becker Muscular Dystrophy (1 trial)
• Cardiomyopathy (1 trial)
• Carrier of Duchenne Muscular Dystrophy (1 trial)
• Diabetes Mellitus, Type 2 (1 trial)
• Duchenne Muscular Dystrophy (DMD) (1 trial)
• Epilepsy (1 trial)
• Idiopathic Pulmonary Fibrosis (IPF) (1 trial)
• Multiple Myeloma (MM) (1 trial)
• Spinal Cord Injury (1 trial)

These new studies include 2 drug trials, 2 device trials, 1 diagnostic test trial, and 1 other type of study. The University of California, Davis is a prominent sponsor of new research this month, leading 3 of the new trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 6 new trials launched this month, 2 are actively seeking healthy volunteers. Across Sacramento, a total of 46 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Sacramento's Leading Research Facilities

Sacramento is home to several leading research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of California Davis Comprehensive Cancer Center (98 trials)
• Mercy Cancer Center - Sacramento (43 trials)
• Sutter Medical Center Sacramento (37 trials)
• Kaiser Permanente-South Sacramento (36 trials)
• Kaiser Permanente Downtown Commons (35 trials)
• UC Davis Medical Center (29 trials)
• University of California, Davis (28 trials)
• University of California Davis (19 trials)
• UC Davis Health (19 trials)
• South Sacramento Cancer Center (16 trials)
• UC Davis (14 trials)
• University of California Davis Health (12 trials)

The University of California, Davis system, with its various affiliated centers and campuses, is a major hub for clinical research in Sacramento, offering a wide array of studies across many medical fields.

Broadening Your Search: Nearby California Options

While Sacramento offers a significant number of clinical trial opportunities, individuals may also find options in other major cities across California. Nearby cities with active trials include Los Angeles (31 trials), San Francisco (17 trials), San Diego (16 trials), Palo Alto (10 trials), La Jolla (9 trials), Stanford (7 trials), Duarte (6 trials), and Walnut Creek (6 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 6 new trials launched this month, 5 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children. Academic institutions, particularly the University of California, Davis, continue to play a vital role in Sacramento's research ecosystem, alongside industry sponsors like AstraZeneca and Eli Lilly and Company.

As we move through June, Sacramento's active research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.